Sevoflurane
General Anesthetic — NERVOUS SYSTEM
Also known as: sevoflo, sevofluran, sevofrane, sevorane
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Sevoflurane is an ofp drug in the General Anesthetic class catalogued in DrugCentral. It was first approved by the FDA in 1995. DrugCentral lists 7 molecular targets, including GLRA1, KCNK2 and KCNK3. Recorded indications include General anesthesia.
- Approval status: ofp (first approved 1995 by the FDA).
- Drug class: General Anesthetic.
- Molecular targets: GLRA1, KCNK2, KCNK3 and KCNK9 (7 listed in DrugCentral).
- Indications: General anesthesia.
- ATC code: N01AB08 (Halogenated hydrocarbons).
- Molecular formula: C4H3F7O; molecular weight 200.06 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- General anesthesia
Contraindications (10)
- Benign intracranial hypertension
- Disease of liver
- Duchenne muscular dystrophy
- Glycosuria
- Hyperkalemia
- Kidney disease
- Low blood pressure
- Malignant hyperthermia
- Proteinuria
- Seizure disorder
Mechanism & targets
| Established pharmacologic class | General Anesthetic |
|---|
Molecular targets (7)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Glycine receptor subunit alpha-1 | GLRA1 | other | — |
| Potassium channel subfamily K member 2 | KCNK2 | opener | — |
| Potassium channel subfamily K member 3 | KCNK3 | opener | — |
| Potassium channel subfamily K member 9 | KCNK9 | opener | — |
| Potassium channel subfamily K member 10 | KCNK10 | opener | — |
| Potassium channel subfamily K member 18 | KCNK18 | opener | — |
| GABA-A receptor; anion channel | GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ | positive allosteric modulator | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1995-06-07 | FDA | — | ABBVIE |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N01AB08 | NERVOUS SYSTEM › ANESTHETICS › ANESTHETICS, GENERAL › Halogenated hydrocarbons |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label
- FDA label: CACNA1S, RYR1 · Actionable PGx
- HCSC label: CACNA1S, RYR1 · Actionable PGx
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Anaesthetic complication neurological | 1919.9 |
| Hyperthermia malignant | 1466.0 |
| Anaesthetic complication | 977.6 |
| Delayed recovery from anaesthesia | 932.7 |
| Unwanted awareness during anaesthesia | 684.7 |
| Anaphylactic shock | 603.3 |
| Cardiac arrest | 593.4 |
| Hypotension | 592.8 |
| Bradycardia | 517.4 |
| Serotonin syndrome | 505.5 |
| Post procedural complication | 473.1 |
| Bronchospasm | 403.2 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Sevoflurane is on its molecule page.
| Molecular formula | C4H3F7O |
|---|---|
| Molecular weight | 200.06 g/mol |
| CAS number | 28523-86-6 |
| InChIKey | DFEYYRMXOJXZRJ-UHFFFAOYSA-N |
| PubChem CID | 5206 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Sevoflurane used for?
DrugCentral lists the following indications for Sevoflurane: General anesthesia.
How does Sevoflurane work?
Its molecular targets in DrugCentral include GLRA1, KCNK2 (opener), KCNK3 (opener) and KCNK9 (opener).
When was Sevoflurane first approved?
Sevoflurane was first approved by the FDA in 1995.
What drug class does Sevoflurane belong to?
Sevoflurane is in the General Anesthetic class.
What is the chemical formula of Sevoflurane?
Sevoflurane has the molecular formula C4H3F7O and a molecular weight of 200.06 g/mol.
Browse: all drugs starting with S · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2439 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200694 — compound record and bioactivity
- PubChem CID 5206 — chemical identifiers
- DrugBank DB01236 — drug record
- FDA UNII 38LVP0K73A — substance identity
- DailyMed: FDA labels for Sevoflurane — current prescribing information (label search)
- UniProt P23415 (GLRA1) — target protein
- UniProt O95069 (KCNK2) — target protein
- UniProt O14649 (KCNK3) — target protein
- UniProt Q9NPC2 (KCNK9) — target protein
- UniProt P57789 (KCNK10) — target protein
- UniProt Q7Z418 (KCNK18) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.